Rhenman & Partners Asset Management’s bluebird bio BLUE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-8,322	Closed	-$5.82M	–	86
2020 Q3	$5.82M	Hold	8,322	–	–	0.52%	60
2020 Q2	$6.58M	Buy	8,322 +3,150	+61%	+$2.38M	0.71%	53
2020 Q1	$3.08M	Buy	5,172 +772	+18%	+$752K	0.43%	66
2019 Q4	$5M	Buy	4,400 +386	+10%	+$420K	0.55%	64
2019 Q3	$4.78M	Sell	4,014 -1,390	-26%	-$2.12M	0.6%	57
2019 Q2	$8.9M	Buy	5,404 +1,158	+27%	+$2M	0.98%	41
2019 Q1	$8.65M	Sell	4,246 -4,852	-53%	-$8.54M	1.01%	41
2018 Q4	$11.7M	Buy	+9,098	New	+$14M	1.34%	37

Other funds holding BLUE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Rhenman & Partners Asset Management's BLUE Position: Q4 2020 in Review

Rhenman & Partners Asset Management sold out of bluebird bio (BLUE) in Q4 2020, closing a stake of 8,322 shares — an estimated $5.82M sold.

Rhenman & Partners Asset Management first reported a position in BLUE in Q4 2018 and held it in 8 quarters. The position peaked at $11.7M in Q4 2018. 262 funds tracked by Wall St. Rank hold BLUE as of Q4 2020.

Rhenman & Partners Asset Management reported no remaining bluebird bio position as of Q4 2020 after selling out during the quarter.
Rhenman & Partners Asset Management sold 8,322 bluebird bio shares in Q4 2020, an estimated $5.82M.
Rhenman & Partners Asset Management first reported a position in bluebird bio in Q4 2018 and held it in 8 quarters.
Rhenman & Partners Asset Management's bluebird bio position peaked at $11.7M in Q4 2018.
262 funds tracked by Wall St. Rank held bluebird bio as of Q4 2020.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2020, filed 19 Jan 2021.